explore -WSS

explore

author：explore 2025-09-28 02:47:36 - browse：4883

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： CDC wastewater surveillance dashboard to track bird flu hotspots

Wikipedia

WSS

Telehealth startups turn to complex chronic diseases

Dairy farmers resist CDC push for PPE against bird flu virus

Readout Newsletter: CAR

Medicare coverage of Wegovy, once blocked, now looks possible

Change Healthcare outage fallout shows need for new oversight

Readout LOUD podcast: brain research, obesity drug sales, Novartis

hotspot

explore

knowledge

Virginia high school admissions case could be legal follow

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

What does generative AI mean for health care? We asked experts

John Green on his newest strategy for fighting tuberculosis

DIEP, the 'gold standard' of breast reconstruction, is under threat

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Apple is now the first public company to be valued at $3 trillion

Study: Adult vaccinations pay for themselves in societal benefits

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

H5N1 bird flu: what we're starting to learn about infection in cows

focus

Readout Newsletter: CAR

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Steward Health Care Massachusetts hospitals face fiscal disaster

Boston's new lab space is opening empty

Steward Health Care files for bankruptcy

Telehealth startups turn to complex chronic diseases

focus

Wikipedia

Wikipedia

explore